Apogem Capital’s Tvardi Therapeutics TVRD Stock Holding History

Apogem Capital’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-500	Closed	-$272K	–	218
2020 Q4	$272K	Buy	+500	New	+$262K	0.18%	137

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Apogem Capital's TVRD Position: Q1 2021 in Review

Apogem Capital sold out of Tvardi Therapeutics (TVRD) in Q1 2021, closing a stake of 500 shares — an estimated $272K sold.

Apogem Capital first reported a position in TVRD in Q4 2020 and held it in 1 quarter. The position peaked at $272K in Q4 2020. 168 funds tracked by Wall St. Rank hold TVRD as of Q1 2021.

Apogem Capital reported no remaining Tvardi Therapeutics position as of Q1 2021 after selling out during the quarter.
Apogem Capital sold 500 Tvardi Therapeutics shares in Q1 2021, an estimated $272K.
Apogem Capital first reported a position in Tvardi Therapeutics in Q4 2020 and held it in 1 quarter.
Apogem Capital's Tvardi Therapeutics position peaked at $272K in Q4 2020.
168 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2021.

Based on Apogem Capital's 13F filing for Q1 2021, filed 14 May 2021.